ArticleThe American journal of tropical medicine and hygiene2026
Development and Validation of an ELISA to Detect Antibody to Onchocerca volvulus Infection Using Mammalian Expressed Recombinant Ov16.
Article in The American journal of tropical medicine and hygiene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Programs designed to eliminate Onchocerca volvulus transmission rely on measurement of Ov16-specific antibodies in children <10 years old and molecular detection of parasites in blackfly vectors. Antibody testing can be conducted using rapid diagnostic tests or an ELISA, depending on location of testing and sample throughput needs. In previous efforts to establish anti-Ov16 testing in endemic country laboratories using existing tests, we encountered difficulties with assay reproducibility, reagent availability and shipping, and user friendliness. To address these challenges, we developed and validated an ELISA using Ov16 recombinant antigen expressed in a mammalian protein expression system that can be completed within 2 hours and does not require refrigeration during shipment. The assay was developed and validated using two distinct sets of dried blood spot samples that included defined positive, negative, and samples from infections with potential cross-reactivity. During development, the ELISA had 92.98% (95% CI = 88.28-97.68%) sensitivity and a specificity of 98.50% (95% CI = 93.80-100%). The cutoff point established during development was then applied to the validation set of specimens, which demonstrated a sensitivity of 89.47% (95% CI = 84.77-94.17%) and 98.32% (95% CI = 93.62-100%) specificity. When repeated over 4 days by 2 different operators, all replicates yielded reproducible results within a coefficient of variance of 20%. In addition, we performed stability testing on assay reagents to evaluate their suitability for shipping at ambient temperatures. The resulting assay will be useful for monitoring anti-Ov16 prevalence in endemic country laboratories.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.